The pharmacological effects of using cabozantinib with a light breakfast
A phase II pharmacokinetic study
Single centre open label randomized cross-over design. Patients will be randomized to start with the experimental or standard regimen. In the experimental regimen, patients will take cabozantinib with a continental breakfast. In the standard regimen, patients will take cabozantinib in fasted state. After all pharmacokinetic samples have been completed, patients will switch to the other regimen.
In order to be eligible to participate in phase A of the study, a subject must meet an additional criterium:
- Cabozantinib trough concentration ≤1125 ng/ml in steady state
LUMC Tom van der Hulle